For the first time in the history of clinical research on male contraception, a non-hormonal drug has demonstrated its safety. The pill YCT-529 was developed at the University of Minnesota and tested in collaboration with Columbia University and YourChoice Therapeutics; it successfully passed the first phase of trials.
The drug did not cause side effects such as mood swings, changes in hormonal balance, sexual function issues, or heart rhythm changes. This is especially important because until now, nearly all attempts to create a pill for men had relied on hormonal mechanisms, which often led to unpleasant and serious adverse reactions. YCT-529 works differently: it blocks a protein that triggers sperm production through vitamin A. As a result, the medicine temporarily suppresses spermatogenesis without affecting hormones, making it unique in its class.
The new pill could fundamentally change the approach to contraception and enable fertility to be controlled safely without hormonal intervention or surgery.
